In vitro and clinical studies of gene therapy with recombinant human adenovirus-p53 injection for oral leukoplakia

Clinical Cancer Research

Volumn 15, Issue 21, 2009, Pages 6724-6731

  Li, Yi ^a   Li, Long Jiang ^a,b   Zhang, Song Tao ^a   Wang, Li Juan ^c   Zhang, Zhuang ^a   Gao, Ning ^a   Zhang, Yuan Yuan ^a   Chen, Qian Ming ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CYCLIN DEPENDENT KINASE INHIBITOR 1; MESSENGER RNA; PROTEIN BCL 2; PROTEIN P53;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG SAFETY; DYSPLASIA; GENE; GENE THERAPY; GROWTH INHIBITION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KERATINOCYTE; LEUKOPLAKIA; P53 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE;

ADENOVIRUSES, HUMAN; CELL LINE; DNA, RECOMBINANT; FEASIBILITY STUDIES; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; LEUKOPLAKIA, ORAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 70350705951     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1296     Document Type: Article

References (47)

1. Axell T, Pindborg JJ, Smith CJ, van der Waal I. Oral white lesions with special reference to pre-cancerousan d tobacco-related lesions: conclusions of an international symposium held in Uppsala, Sweden, May 18-21 1994. International Collaborative Group on Oral White Lesions. J Oral Pathol Med 1996;25:49-54. (Pubitemid 2617616)
2. Liu SC, Klein-Szanto AJ. Markers of proliferation in normal and leukoplakic oral epithelia. Oral Oncol 2000;36:145-151
3. Reibel J. Prognosis of oral pre-malignant lesions: significance of clinical, histopathological, and molecular biological characteristics. Crit Rev Oral Biol Med 2003;14:47-62.
4. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-156
5. Gleich LL, Salamone FN. Molecular geneticsof head and neck cancer. Cancer Control 2002;9: 369-378 (Pubitemid 35204459)
6. Vora HH, Trivedi TI, Shukla SN, Shah NG, Goswami JV, Shah PM. p53 expression in leukoplakia and carcinoma of the tongue. Int J Biol Markers2006;21:74-80.
7. RiesJC, Schreiner D, Steininger H, Girod SC. p53 mutation and detection of p53 protein expression in oral leukoplakia and oral squamouscell carcinoma. Anticancer Res1998;18:2031-2036
8. Sakai E, Ts uchida N. Mos t human squamous cell carcinomasin the oral cavity contain mutated p53 tumor-suppressor genes. Oncogene 1992;7:927-933
9. Tetu B, Brisson J, Plante V, Bernard P. p53 and c-erbB- 2 as markers of resistance to adjuvant chemotherapy in breast cancer. Mod Pathol 1998;11: 823-830 (Pubitemid 28440878)
10. 2/M arrest by infection with replication-deficient adenovirusa t high multiplicity of infection. Gene Ther 1999;6:1054-1063
11. Buller RE, Runnebaum IB, Karlan BY, et al. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther 2002;9:553-566 (Pubitemid 34734419)
12. Lang FF, Bruner JM, Fuller GN, et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol 2003;21:2508-2518
13. Modesitt SC, Ramirez P, Zu Z, Bodurka-Bevers D, Gershenson D, Wolf JK. In vitro and in vivo adenovirus-mediated p53 and p16 tumor suppressor therapy in ovarian cancer. Clin Cancer Res2001;7:1765-1772
14. Schuler M, Herrmann R, De Greve JL, et al. Adenovirus- mediated wild-type p53 gene transfer in patientsreceiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. J Clin Oncol 2001; 19:1750-1758 (Pubitemid 32230877)
15. Spitz FR, Nguyen D, Skibber JM, Meyn RE, Cristiano RJ, Roth JA. Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clin Cancer Res1996;2:1665-1671
16. Pan JJ, Zhang SW, Chen CB, et al. Effect of recombinant adenovirus-p53 combined with radiotherapy on long-term prognosis of advanced nasopharyngeal carcinoma. J Clin Oncol 2009; 27:799-804.
17. Weill D, Mack M, Roth J, et al. Adenoviral-mediated p53 gene transfer to non-small cell lung cancer through endobronchial injection. Chest 2000;118:966-970 (Pubitemid 30796886)
18. Pagliaro LC, Keyhani A, WilliamsD, et al. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy. J Clin Oncol 2003;21:2247-2253
19. Reid T, Warren R, Kirn D. Intravascular adeno-viral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther 2002;9:979-986 (Pubitemid 35462561)
20. Sankaranarayanan R, Mathew B, Varghese C, et al. Chemoprevention of oral leukoplakia with vitamin A and β carotene: an assessment. Oral Oncol 1997;33:231-236 (Pubitemid 27376845)
21. Scardina GA, Carini F, Maresi E, Valenza V, Messina P. Evaluation of the clinical and histological effectiveness of isotretinoin in the therapy of oral leukoplakia: ten yearsof experience: is management still up to date and effective? Methods Find Exp Clin Pharmacol 2006;28:115-119
22. Shimizu M, Saitoh Y, Itoh H. Immunohis-tochemical staining of Ha-ras oncogene product in normal, benign, and malignant human pancreatic tissues. Hum Pathol 1990;21:607-612 (Pubitemid 20204948)
23. Linzer DI, Levine AJ. Characterization of a 54 K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 1979;17:43-52. (Pubitemid 9188209)
24. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutationsin human cancers. Science 1991;253:49-53. (Pubitemid 21917115)
25. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-331
26. Balint EE, Vousden KH. Activation and activities of the p53 tumour suppressor protein. Br J Cancer 2001;85:1813-1823 (Pubitemid 34775315)
27. HarrisC C. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996; 88:1442-1455
28. Pisters LL, Pettaway CA, Troncoso P, et al. Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer. Clin Cancer Res2004;10:2587-2593
29. Higuchi Y, Asaumi J, Murakami J, et al. Effects of p53 gene therapy in radiotherapy or thermotherapy of human head and neck squamous cell carcinoma cell lines. Oncol Rep 2003;10:671-677
30. Huang Y, Jin Y, Yan CH, et al. Involvement of Annexin A2 in p53 induced apoptosis in lung cancer. Mol Cell Biochem 2008;309:117-123
31. Kornberg L. Ad-fRNK and Ad-p53 cooperate to augment drug-induced death of a transformed cell line. Anticancer Res2006;26:3025-3031
32. Quist SR, Wang-Gohrke S, Kohler T, Kreienberg R, Runnebaum IB. Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cellsindependent of the endogenous p53 status. Cancer Gene Ther 2004;11:547-554 (Pubitemid 39079493)
33. Romano G, Michell P, Pacilio C, Giordano A. Latest developments in gene transfer technology: achievements, perspectives, and controversies over therapeutic applications. Stem Cells2000;18:19-39.
34. Walters RW, Grunst T, Bergelson JM, Finberg RW, Welsh MJ, Zabner J. Basolateral localization of fiber receptorslimitsadenovirusinfection from the apical surface of airway epithelia. J Biol Chem 1999;274:10219-10226 (Pubitemid 129518312)
35. Frey BM, Hackett NR, Bergelson JM, et al. High-efficiency gene transfer into ex vivo expanded human hematopoietic progenitorsa nd precursor cellsby adenovirus vectors. Blood 1998;91:2781-2792
36. Johnson KT, Rodicker F, Heise K, et al. Adenoviral p53 gene transfer inhibits human Tenon's capsule fibroblast proliferation. Br J Ophthalmol 2005;89:508-512 (Pubitemid 40469976)
37. Lou J, Xu F, Merkel K, Manske P. Gene therapy: adenovirus-mediated human bone morphogenetic protein-2 gene transfer induces mesenchymal progenitor cell proliferation and differentiation in vitro and bone formation in vivo. J Orthop Res 1999;17:43-50. (Pubitemid 29096004)
38. Watanabe T, Kuszynski C, Ino K, et al. Gene transfer into human bone marrow hematopoietic cellsm ediated by adenovirus vectors. Blood 1996;87:5032-5039 (Pubitemid 26189844)
39. Peter M, Herskowitz I. Joining the complex: cyclin- dependent kinase inhibitory proteins and the cell cycle. Cell 1994;79:181-184 (Pubitemid 24324907)
40. Rieder CL, Cole RW, Khodjakov A, Sluder G. The checkpoint delaying anaphase in response to chromosome monoorientation is mediated by an inhibitory signal produced by unattached kinetochores. J Cell Biol 1995;130:941-948
41. Bartek J, Lukas J. Mammalian G1- and S-phase checkpoints in response to DNA damage. Curr Opin Cell Biol 2001;13:738-747
42. Von Gruenigen VE, O'Boyle JD, Coleman RL, Wilson D, Miller DS, Mathis JM. Efficacy of intraperitoneal adenovirus-mediated p53 gene therapy in ovarian cancer. Int J Gynecol Cancer 1999; 9:365-372
43. Wu Q, Kirschmeier P, Hockenberry T, et al. Transcriptional regulation during p21WAF1/ CIP1-induced apoptosis in human ovarian cancer cells. J Biol Chem 2002;277:36329-36337
44. Stewart ZA, Pietenpol JA. p53 Signaling and cell cycle checkpoints. Chem Res Toxicol 2001;14:243-263
45. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 isa potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-816 (Pubitemid 23346377)
46. Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 1995;55: 5187-5190
47. Haupt S, Berger M, Goldberg Z, Haupt Y. Apoptosis-the p53 network. J Cell Sci 2003; 116:4077-4085